TTN

Across TCGA pan-cancer cohorts, TTN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TTN data layer compared with 21 for mass-spec protein and 20 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TTN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TTN expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

GBM, HNSC, and LUAD are the cancer types where TTN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.852	0.782	.009	7	view →
HNSC	DFS	Quartile	All	1.000	0.379	.036	7	view →
LUAD	OS	Quartile	II,III,IV	0.826	0.455	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TTN–GBM (OS)

Open the GBM breakdown →